Peptide Degrader‐Based Targeting of METTL3/14 Improves Immunotherapy Response in Cutaneous Melanoma
Angewandte Chemie International Edition · 25.11.2024 · 63 (48)
DOI: 10.1002/anie.202407381 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 29.10.2024. Verfasst von Hong Han und 7 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Hospital of Hunan University, School of Biomedical Sciences, Hunan University, Changsha, P. R. China. Hauptthemen laut MEDLINE: Methyltransferases, Melanoma, Immunotherapy, Peptides. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 89 Literaturangaben. Gefördert von: National Science Foundation of China, Science Fund for Distinguished Young Scholars of Hunan Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
METTL3 has emerged as a promising therapeutic target in cancer treatment, although its oncogenic functions in melanoma development and potential for therapeutic targeting drug have not been fully explored. In this study, we define the oncogenic role of METTL3 in melanoma development and progression. Building on this insight, we examine our recently designed peptide inhibitor RM3 , which targets the binding interface of METTL3/14 complex for disruption and subsequent ubiquitin‐mediated proteasomal degradation via the E3 ligase STUB1. RM3 treatment reduces proliferation, migration, and invasion, and induces apoptosis in melanoma cells in vitro and in vivo. Subsequent transcriptomic analysis identified changes in immuno‐related genes following RM3 ‐mediated suppression of METTL3/14 N 6 ‐methyladenosine (m 6 A) methyltransferase activity, suggesting a potential for interaction with immunotherapy. A combination treatment of RM3 with anti‐PD‐1 antibody results in significantly higher beneficial tumor response in vivo, with a good safety profile. Collectively, these findings not only delineate the oncogenic role of METTL3 in melanoma but also showcase RM3 , acting as a peptide degrader, as a novel and promising strategy for melanoma treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Affiliated Hospital of Hunan University, School of Biomedical Sciences, Hunan University, Changsha, P. R. China.
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, P. R. China.
- Affiliated Hospital of Hunan University, Department of Infectious Disease and Public Health, Hunan province, P. R. China.
- Shenzhen Research Institute, Hunan University, Shenzhen, Guangdong, 518000, P. R. China.
ORCID-Profile: Hong Han, Dan Yuan, Junfeng Shi
Förderung
- National Science Foundation of China
- Science Fund for Distinguished Young Scholars of Hunan Province
- National Natural Science Foundation of China
Zitieren
APA
Han, H., Li, Z., Feng, Y., Song, H., Fang, Z., Zhang, D., Yuan, D., & Shi, J. (2024). Peptide Degrader‐Based Targeting of METTL3/14 Improves Immunotherapy Response in Cutaneous Melanoma. Angewandte Chemie International Edition, 63(48). https://doi.org/10.1002/anie.202407381
Vancouver
Han H, Li Z, Feng Y, Song H, Fang Z, Zhang D, et al. Peptide Degrader‐Based Targeting of METTL3/14 Improves Immunotherapy Response in Cutaneous Melanoma. Angewandte Chemie International Edition. 2024;63(48). doi:10.1002/anie.202407381
BibTeX
@article{Han2024,
author = {Han, Hong and Li, Zenghui and Feng, Yuqing and Song, He and Fang, Zhixiong and Zhang, Dingxiao and Yuan, Dan and Shi, Junfeng},
title = {Peptide Degrader‐Based Targeting of METTL3/14 Improves Immunotherapy Response in Cutaneous Melanoma},
journal = {Angewandte Chemie International Edition},
year = {2024},
volume = {63},
number = {48},
doi = {10.1002/anie.202407381}
}
EUVIMED